nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoversetamide—Diarrhoea haemorrhagic—Docetaxel—head and neck cancer	0.0279	0.0279	CcSEcCtD
Gadoversetamide—Gastrointestinal perforation—Docetaxel—head and neck cancer	0.027	0.027	CcSEcCtD
Gadoversetamide—Application site reaction—Fluorouracil—head and neck cancer	0.0208	0.0208	CcSEcCtD
Gadoversetamide—Numbness—Vinblastine—head and neck cancer	0.0179	0.0179	CcSEcCtD
Gadoversetamide—Local reaction—Fluorouracil—head and neck cancer	0.0176	0.0176	CcSEcCtD
Gadoversetamide—Sensory loss—Vinblastine—head and neck cancer	0.0172	0.0172	CcSEcCtD
Gadoversetamide—Creatinine increased—Hydroxyurea—head and neck cancer	0.0142	0.0142	CcSEcCtD
Gadoversetamide—Numbness—Fluorouracil—head and neck cancer	0.0118	0.0118	CcSEcCtD
Gadoversetamide—Sensory loss—Fluorouracil—head and neck cancer	0.0113	0.0113	CcSEcCtD
Gadoversetamide—Disorientation—Hydroxyurea—head and neck cancer	0.011	0.011	CcSEcCtD
Gadoversetamide—Parosmia—Docetaxel—head and neck cancer	0.0109	0.0109	CcSEcCtD
Gadoversetamide—Herpes simplex—Fluorouracil—head and neck cancer	0.0106	0.0106	CcSEcCtD
Gadoversetamide—Haemoglobin decreased—Docetaxel—head and neck cancer	0.0102	0.0102	CcSEcCtD
Gadoversetamide—Burning sensation—Docetaxel—head and neck cancer	0.0101	0.0101	CcSEcCtD
Gadoversetamide—Face oedema—Hydroxyurea—head and neck cancer	0.0095	0.0095	CcSEcCtD
Gadoversetamide—Blood creatinine increased—Hydroxyurea—head and neck cancer	0.00922	0.00922	CcSEcCtD
Gadoversetamide—Rhinorrhoea—Docetaxel—head and neck cancer	0.0087	0.0087	CcSEcCtD
Gadoversetamide—Thrombophlebitis—Fluorouracil—head and neck cancer	0.00819	0.00819	CcSEcCtD
Gadoversetamide—Chest discomfort—Docetaxel—head and neck cancer	0.00796	0.00796	CcSEcCtD
Gadoversetamide—Dysuria—Hydroxyurea—head and neck cancer	0.00796	0.00796	CcSEcCtD
Gadoversetamide—Disorientation—Fluorouracil—head and neck cancer	0.00792	0.00792	CcSEcCtD
Gadoversetamide—Oliguria—Docetaxel—head and neck cancer	0.00765	0.00765	CcSEcCtD
Gadoversetamide—Amnesia—Fluorouracil—head and neck cancer	0.00754	0.00754	CcSEcCtD
Gadoversetamide—Haemoglobin—Vinblastine—head and neck cancer	0.00751	0.00751	CcSEcCtD
Gadoversetamide—Haemorrhage—Vinblastine—head and neck cancer	0.00747	0.00747	CcSEcCtD
Gadoversetamide—Hypoaesthesia—Vinblastine—head and neck cancer	0.00743	0.00743	CcSEcCtD
Gadoversetamide—Pharyngitis—Vinblastine—head and neck cancer	0.00741	0.00741	CcSEcCtD
Gadoversetamide—Injection site reaction—Docetaxel—head and neck cancer	0.007	0.007	CcSEcCtD
Gadoversetamide—Haemoglobin—Hydroxyurea—head and neck cancer	0.00685	0.00685	CcSEcCtD
Gadoversetamide—Haemorrhage—Hydroxyurea—head and neck cancer	0.00681	0.00681	CcSEcCtD
Gadoversetamide—Hallucination—Hydroxyurea—head and neck cancer	0.00678	0.00678	CcSEcCtD
Gadoversetamide—Dry skin—Fluorouracil—head and neck cancer	0.0065	0.0065	CcSEcCtD
Gadoversetamide—Nasopharyngitis—Fluorouracil—head and neck cancer	0.00634	0.00634	CcSEcCtD
Gadoversetamide—Muscular weakness—Fluorouracil—head and neck cancer	0.00625	0.00625	CcSEcCtD
Gadoversetamide—Angiopathy—Hydroxyurea—head and neck cancer	0.00618	0.00618	CcSEcCtD
Gadoversetamide—Dysphagia—Fluorouracil—head and neck cancer	0.00612	0.00612	CcSEcCtD
Gadoversetamide—Chills—Hydroxyurea—head and neck cancer	0.00611	0.00611	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Vinblastine—head and neck cancer	0.00603	0.00603	CcSEcCtD
Gadoversetamide—Erythema—Hydroxyurea—head and neck cancer	0.00593	0.00593	CcSEcCtD
Gadoversetamide—Thrombophlebitis—Docetaxel—head and neck cancer	0.00591	0.00591	CcSEcCtD
Gadoversetamide—Malaise—Vinblastine—head and neck cancer	0.00586	0.00586	CcSEcCtD
Gadoversetamide—Vertigo—Vinblastine—head and neck cancer	0.00584	0.00584	CcSEcCtD
Gadoversetamide—Convulsion—Vinblastine—head and neck cancer	0.00563	0.00563	CcSEcCtD
Gadoversetamide—Hypertension—Vinblastine—head and neck cancer	0.00561	0.00561	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.0055	0.0055	CcSEcCtD
Gadoversetamide—Pneumonia—Fluorouracil—head and neck cancer	0.00549	0.00549	CcSEcCtD
Gadoversetamide—Discomfort—Vinblastine—head and neck cancer	0.00547	0.00547	CcSEcCtD
Gadoversetamide—Malaise—Hydroxyurea—head and neck cancer	0.00535	0.00535	CcSEcCtD
Gadoversetamide—Conjunctivitis—Fluorouracil—head and neck cancer	0.00531	0.00531	CcSEcCtD
Gadoversetamide—Urinary tract infection—Fluorouracil—head and neck cancer	0.00531	0.00531	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Vinblastine—head and neck cancer	0.0052	0.0052	CcSEcCtD
Gadoversetamide—Epistaxis—Fluorouracil—head and neck cancer	0.00515	0.00515	CcSEcCtD
Gadoversetamide—Convulsion—Hydroxyurea—head and neck cancer	0.00514	0.00514	CcSEcCtD
Gadoversetamide—Hyponatraemia—Docetaxel—head and neck cancer	0.00514	0.00514	CcSEcCtD
Gadoversetamide—Sinusitis—Fluorouracil—head and neck cancer	0.00512	0.00512	CcSEcCtD
Gadoversetamide—Anorexia—Vinblastine—head and neck cancer	0.00506	0.00506	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00501	0.00501	CcSEcCtD
Gadoversetamide—Discomfort—Hydroxyurea—head and neck cancer	0.00499	0.00499	CcSEcCtD
Gadoversetamide—Haemoglobin—Fluorouracil—head and neck cancer	0.00493	0.00493	CcSEcCtD
Gadoversetamide—Rhinitis—Fluorouracil—head and neck cancer	0.00491	0.00491	CcSEcCtD
Gadoversetamide—Haemorrhage—Fluorouracil—head and neck cancer	0.0049	0.0049	CcSEcCtD
Gadoversetamide—Hypoaesthesia—Fluorouracil—head and neck cancer	0.00488	0.00488	CcSEcCtD
Gadoversetamide—Pharyngitis—Fluorouracil—head and neck cancer	0.00487	0.00487	CcSEcCtD
Gadoversetamide—Oedema—Hydroxyurea—head and neck cancer	0.00484	0.00484	CcSEcCtD
Gadoversetamide—Paraesthesia—Vinblastine—head and neck cancer	0.00476	0.00476	CcSEcCtD
Gadoversetamide—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00475	0.00475	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.00474	0.00474	CcSEcCtD
Gadoversetamide—Skin disorder—Hydroxyurea—head and neck cancer	0.0047	0.0047	CcSEcCtD
Gadoversetamide—Dry skin—Docetaxel—head and neck cancer	0.00469	0.00469	CcSEcCtD
Gadoversetamide—Anorexia—Hydroxyurea—head and neck cancer	0.00461	0.00461	CcSEcCtD
Gadoversetamide—Decreased appetite—Vinblastine—head and neck cancer	0.00461	0.00461	CcSEcCtD
Gadoversetamide—Nasopharyngitis—Docetaxel—head and neck cancer	0.00457	0.00457	CcSEcCtD
Gadoversetamide—Pain—Vinblastine—head and neck cancer	0.00454	0.00454	CcSEcCtD
Gadoversetamide—Constipation—Vinblastine—head and neck cancer	0.00454	0.00454	CcSEcCtD
Gadoversetamide—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.00451	0.00451	CcSEcCtD
Gadoversetamide—Dysphagia—Docetaxel—head and neck cancer	0.00442	0.00442	CcSEcCtD
Gadoversetamide—Arrhythmia—Fluorouracil—head and neck cancer	0.00438	0.00438	CcSEcCtD
Gadoversetamide—Feeling abnormal—Vinblastine—head and neck cancer	0.00437	0.00437	CcSEcCtD
Gadoversetamide—Bronchospasm—Docetaxel—head and neck cancer	0.00435	0.00435	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00434	0.00434	CcSEcCtD
Gadoversetamide—Dyspnoea—Hydroxyurea—head and neck cancer	0.00431	0.00431	CcSEcCtD
Gadoversetamide—Somnolence—Hydroxyurea—head and neck cancer	0.0043	0.0043	CcSEcCtD
Gadoversetamide—Erythema—Fluorouracil—head and neck cancer	0.00427	0.00427	CcSEcCtD
Gadoversetamide—Dyspepsia—Hydroxyurea—head and neck cancer	0.00426	0.00426	CcSEcCtD
Gadoversetamide—Decreased appetite—Hydroxyurea—head and neck cancer	0.00421	0.00421	CcSEcCtD
Gadoversetamide—Abdominal pain—Vinblastine—head and neck cancer	0.00419	0.00419	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00418	0.00418	CcSEcCtD
Gadoversetamide—Fatigue—Hydroxyurea—head and neck cancer	0.00417	0.00417	CcSEcCtD
Gadoversetamide—Constipation—Hydroxyurea—head and neck cancer	0.00414	0.00414	CcSEcCtD
Gadoversetamide—Pain—Hydroxyurea—head and neck cancer	0.00414	0.00414	CcSEcCtD
Gadoversetamide—Vision blurred—Fluorouracil—head and neck cancer	0.00402	0.00402	CcSEcCtD
Gadoversetamide—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00399	0.00399	CcSEcCtD
Gadoversetamide—Pneumonia—Docetaxel—head and neck cancer	0.00396	0.00396	CcSEcCtD
Gadoversetamide—Hypersensitivity—Vinblastine—head and neck cancer	0.00391	0.00391	CcSEcCtD
Gadoversetamide—Conjunctivitis—Docetaxel—head and neck cancer	0.00383	0.00383	CcSEcCtD
Gadoversetamide—Body temperature increased—Hydroxyurea—head and neck cancer	0.00383	0.00383	CcSEcCtD
Gadoversetamide—Asthenia—Vinblastine—head and neck cancer	0.00381	0.00381	CcSEcCtD
Gadoversetamide—Epistaxis—Docetaxel—head and neck cancer	0.00372	0.00372	CcSEcCtD
Gadoversetamide—Convulsion—Fluorouracil—head and neck cancer	0.0037	0.0037	CcSEcCtD
Gadoversetamide—Myalgia—Fluorouracil—head and neck cancer	0.00363	0.00363	CcSEcCtD
Gadoversetamide—Chest pain—Fluorouracil—head and neck cancer	0.00363	0.00363	CcSEcCtD
Gadoversetamide—Diarrhoea—Vinblastine—head and neck cancer	0.00363	0.00363	CcSEcCtD
Gadoversetamide—Discomfort—Fluorouracil—head and neck cancer	0.00359	0.00359	CcSEcCtD
Gadoversetamide—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00357	0.00357	CcSEcCtD
Gadoversetamide—Haemoglobin—Docetaxel—head and neck cancer	0.00356	0.00356	CcSEcCtD
Gadoversetamide—Rhinitis—Docetaxel—head and neck cancer	0.00355	0.00355	CcSEcCtD
Gadoversetamide—Haemorrhage—Docetaxel—head and neck cancer	0.00354	0.00354	CcSEcCtD
Gadoversetamide—Hypoaesthesia—Docetaxel—head and neck cancer	0.00352	0.00352	CcSEcCtD
Gadoversetamide—Confusional state—Fluorouracil—head and neck cancer	0.00351	0.00351	CcSEcCtD
Gadoversetamide—Pharyngitis—Docetaxel—head and neck cancer	0.00351	0.00351	CcSEcCtD
Gadoversetamide—Dizziness—Vinblastine—head and neck cancer	0.00351	0.00351	CcSEcCtD
Gadoversetamide—Urinary tract disorder—Docetaxel—head and neck cancer	0.00349	0.00349	CcSEcCtD
Gadoversetamide—Oedema peripheral—Docetaxel—head and neck cancer	0.00349	0.00349	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Fluorouracil—head and neck cancer	0.00348	0.00348	CcSEcCtD
Gadoversetamide—Oedema—Fluorouracil—head and neck cancer	0.00348	0.00348	CcSEcCtD
Gadoversetamide—Asthenia—Hydroxyurea—head and neck cancer	0.00347	0.00347	CcSEcCtD
Gadoversetamide—Urethral disorder—Docetaxel—head and neck cancer	0.00347	0.00347	CcSEcCtD
Gadoversetamide—Nervous system disorder—Fluorouracil—head and neck cancer	0.00342	0.00342	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Fluorouracil—head and neck cancer	0.00341	0.00341	CcSEcCtD
Gadoversetamide—Tachycardia—Fluorouracil—head and neck cancer	0.0034	0.0034	CcSEcCtD
Gadoversetamide—Vomiting—Vinblastine—head and neck cancer	0.00337	0.00337	CcSEcCtD
Gadoversetamide—Erythema multiforme—Docetaxel—head and neck cancer	0.00335	0.00335	CcSEcCtD
Gadoversetamide—Headache—Vinblastine—head and neck cancer	0.00332	0.00332	CcSEcCtD
Gadoversetamide—Anorexia—Fluorouracil—head and neck cancer	0.00332	0.00332	CcSEcCtD
Gadoversetamide—Diarrhoea—Hydroxyurea—head and neck cancer	0.00331	0.00331	CcSEcCtD
Gadoversetamide—Eye disorder—Docetaxel—head and neck cancer	0.00331	0.00331	CcSEcCtD
Gadoversetamide—Flushing—Docetaxel—head and neck cancer	0.00328	0.00328	CcSEcCtD
Gadoversetamide—Cardiac disorder—Docetaxel—head and neck cancer	0.00328	0.00328	CcSEcCtD
Gadoversetamide—Hypotension—Fluorouracil—head and neck cancer	0.00325	0.00325	CcSEcCtD
Gadoversetamide—Angiopathy—Docetaxel—head and neck cancer	0.00321	0.00321	CcSEcCtD
Gadoversetamide—Dizziness—Hydroxyurea—head and neck cancer	0.0032	0.0032	CcSEcCtD
Gadoversetamide—Immune system disorder—Docetaxel—head and neck cancer	0.0032	0.0032	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Docetaxel—head and neck cancer	0.00319	0.00319	CcSEcCtD
Gadoversetamide—Chills—Docetaxel—head and neck cancer	0.00317	0.00317	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00317	0.00317	CcSEcCtD
Gadoversetamide—Arrhythmia—Docetaxel—head and neck cancer	0.00316	0.00316	CcSEcCtD
Gadoversetamide—Nausea—Vinblastine—head and neck cancer	0.00315	0.00315	CcSEcCtD
Gadoversetamide—Insomnia—Fluorouracil—head and neck cancer	0.00315	0.00315	CcSEcCtD
Gadoversetamide—Paraesthesia—Fluorouracil—head and neck cancer	0.00313	0.00313	CcSEcCtD
Gadoversetamide—Dyspnoea—Fluorouracil—head and neck cancer	0.00311	0.00311	CcSEcCtD
Gadoversetamide—Mental disorder—Docetaxel—head and neck cancer	0.0031	0.0031	CcSEcCtD
Gadoversetamide—Somnolence—Fluorouracil—head and neck cancer	0.0031	0.0031	CcSEcCtD
Gadoversetamide—Malnutrition—Docetaxel—head and neck cancer	0.00308	0.00308	CcSEcCtD
Gadoversetamide—Erythema—Docetaxel—head and neck cancer	0.00308	0.00308	CcSEcCtD
Gadoversetamide—Vomiting—Hydroxyurea—head and neck cancer	0.00308	0.00308	CcSEcCtD
Gadoversetamide—Dyspepsia—Fluorouracil—head and neck cancer	0.00307	0.00307	CcSEcCtD
Gadoversetamide—Rash—Hydroxyurea—head and neck cancer	0.00305	0.00305	CcSEcCtD
Gadoversetamide—Dermatitis—Hydroxyurea—head and neck cancer	0.00305	0.00305	CcSEcCtD
Gadoversetamide—Headache—Hydroxyurea—head and neck cancer	0.00303	0.00303	CcSEcCtD
Gadoversetamide—Decreased appetite—Fluorouracil—head and neck cancer	0.00303	0.00303	CcSEcCtD
Gadoversetamide—Dysgeusia—Docetaxel—head and neck cancer	0.00302	0.00302	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00301	0.00301	CcSEcCtD
Gadoversetamide—Back pain—Docetaxel—head and neck cancer	0.00298	0.00298	CcSEcCtD
Gadoversetamide—Pain—Fluorouracil—head and neck cancer	0.00298	0.00298	CcSEcCtD
Gadoversetamide—Muscle spasms—Docetaxel—head and neck cancer	0.00296	0.00296	CcSEcCtD
Gadoversetamide—Nausea—Hydroxyurea—head and neck cancer	0.00287	0.00287	CcSEcCtD
Gadoversetamide—Feeling abnormal—Fluorouracil—head and neck cancer	0.00287	0.00287	CcSEcCtD
Gadoversetamide—Urticaria—Fluorouracil—head and neck cancer	0.00277	0.00277	CcSEcCtD
Gadoversetamide—Syncope—Docetaxel—head and neck cancer	0.00276	0.00276	CcSEcCtD
Gadoversetamide—Body temperature increased—Fluorouracil—head and neck cancer	0.00275	0.00275	CcSEcCtD
Gadoversetamide—Palpitations—Docetaxel—head and neck cancer	0.00272	0.00272	CcSEcCtD
Gadoversetamide—Loss of consciousness—Docetaxel—head and neck cancer	0.00271	0.00271	CcSEcCtD
Gadoversetamide—Cough—Docetaxel—head and neck cancer	0.00269	0.00269	CcSEcCtD
Gadoversetamide—Convulsion—Docetaxel—head and neck cancer	0.00267	0.00267	CcSEcCtD
Gadoversetamide—Hypertension—Docetaxel—head and neck cancer	0.00266	0.00266	CcSEcCtD
Gadoversetamide—Myalgia—Docetaxel—head and neck cancer	0.00262	0.00262	CcSEcCtD
Gadoversetamide—Arthralgia—Docetaxel—head and neck cancer	0.00262	0.00262	CcSEcCtD
Gadoversetamide—Chest pain—Docetaxel—head and neck cancer	0.00262	0.00262	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.0026	0.0026	CcSEcCtD
Gadoversetamide—Hypersensitivity—Fluorouracil—head and neck cancer	0.00257	0.00257	CcSEcCtD
Gadoversetamide—Dry mouth—Docetaxel—head and neck cancer	0.00256	0.00256	CcSEcCtD
Gadoversetamide—Confusional state—Docetaxel—head and neck cancer	0.00253	0.00253	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Docetaxel—head and neck cancer	0.00251	0.00251	CcSEcCtD
Gadoversetamide—Oedema—Docetaxel—head and neck cancer	0.00251	0.00251	CcSEcCtD
Gadoversetamide—Shock—Docetaxel—head and neck cancer	0.00247	0.00247	CcSEcCtD
Gadoversetamide—Nervous system disorder—Docetaxel—head and neck cancer	0.00247	0.00247	CcSEcCtD
Gadoversetamide—Pruritus—Fluorouracil—head and neck cancer	0.00246	0.00246	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Docetaxel—head and neck cancer	0.00246	0.00246	CcSEcCtD
Gadoversetamide—Tachycardia—Docetaxel—head and neck cancer	0.00245	0.00245	CcSEcCtD
Gadoversetamide—Skin disorder—Docetaxel—head and neck cancer	0.00244	0.00244	CcSEcCtD
Gadoversetamide—Anorexia—Docetaxel—head and neck cancer	0.0024	0.0024	CcSEcCtD
Gadoversetamide—Diarrhoea—Fluorouracil—head and neck cancer	0.00238	0.00238	CcSEcCtD
Gadoversetamide—Hypotension—Docetaxel—head and neck cancer	0.00235	0.00235	CcSEcCtD
Gadoversetamide—Dizziness—Fluorouracil—head and neck cancer	0.0023	0.0023	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.00229	0.00229	CcSEcCtD
Gadoversetamide—Insomnia—Docetaxel—head and neck cancer	0.00227	0.00227	CcSEcCtD
Gadoversetamide—Paraesthesia—Docetaxel—head and neck cancer	0.00226	0.00226	CcSEcCtD
Gadoversetamide—Dyspnoea—Docetaxel—head and neck cancer	0.00224	0.00224	CcSEcCtD
Gadoversetamide—Somnolence—Docetaxel—head and neck cancer	0.00223	0.00223	CcSEcCtD
Gadoversetamide—Vomiting—Fluorouracil—head and neck cancer	0.00221	0.00221	CcSEcCtD
Gadoversetamide—Dyspepsia—Docetaxel—head and neck cancer	0.00221	0.00221	CcSEcCtD
Gadoversetamide—Rash—Fluorouracil—head and neck cancer	0.0022	0.0022	CcSEcCtD
Gadoversetamide—Dermatitis—Fluorouracil—head and neck cancer	0.00219	0.00219	CcSEcCtD
Gadoversetamide—Decreased appetite—Docetaxel—head and neck cancer	0.00219	0.00219	CcSEcCtD
Gadoversetamide—Headache—Fluorouracil—head and neck cancer	0.00218	0.00218	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00217	0.00217	CcSEcCtD
Gadoversetamide—Fatigue—Docetaxel—head and neck cancer	0.00217	0.00217	CcSEcCtD
Gadoversetamide—Constipation—Docetaxel—head and neck cancer	0.00215	0.00215	CcSEcCtD
Gadoversetamide—Pain—Docetaxel—head and neck cancer	0.00215	0.00215	CcSEcCtD
Gadoversetamide—Feeling abnormal—Docetaxel—head and neck cancer	0.00207	0.00207	CcSEcCtD
Gadoversetamide—Nausea—Fluorouracil—head and neck cancer	0.00207	0.00207	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Docetaxel—head and neck cancer	0.00206	0.00206	CcSEcCtD
Gadoversetamide—Abdominal pain—Docetaxel—head and neck cancer	0.00199	0.00199	CcSEcCtD
Gadoversetamide—Body temperature increased—Docetaxel—head and neck cancer	0.00199	0.00199	CcSEcCtD
Gadoversetamide—Hypersensitivity—Docetaxel—head and neck cancer	0.00185	0.00185	CcSEcCtD
Gadoversetamide—Asthenia—Docetaxel—head and neck cancer	0.0018	0.0018	CcSEcCtD
Gadoversetamide—Pruritus—Docetaxel—head and neck cancer	0.00178	0.00178	CcSEcCtD
Gadoversetamide—Diarrhoea—Docetaxel—head and neck cancer	0.00172	0.00172	CcSEcCtD
Gadoversetamide—Dizziness—Docetaxel—head and neck cancer	0.00166	0.00166	CcSEcCtD
Gadoversetamide—Vomiting—Docetaxel—head and neck cancer	0.0016	0.0016	CcSEcCtD
Gadoversetamide—Rash—Docetaxel—head and neck cancer	0.00159	0.00159	CcSEcCtD
Gadoversetamide—Dermatitis—Docetaxel—head and neck cancer	0.00158	0.00158	CcSEcCtD
Gadoversetamide—Headache—Docetaxel—head and neck cancer	0.00157	0.00157	CcSEcCtD
Gadoversetamide—Nausea—Docetaxel—head and neck cancer	0.00149	0.00149	CcSEcCtD
